A study to investigate the safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of a single subcutaneous dose of GSK4771261 in healthy participants aged 25 to 55 years of age inclusive

2025-525073-37-00 Protocol 221377 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 12 May 2026 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol 221377

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 30
Countries 1
Sites 1

Autosomal Dominant Polycystic Kidney Disease

Key facts

Sponsor
Glaxosmithkline Research & Development Limited
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trial duration
12 May 2026 → ongoing
Decision date (initial)
2026-05-06
Transition trial
No
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Autosomal Dominant Polycystic Kidney Disease

VersionLevelCodeTermSystem organ class
20.0 LLT 10036046 Polycystic kidney autosomal dominant 10010331

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Glaxosmithkline Research & Development Limited

Sponsor organisation
Glaxosmithkline Research & Development Limited
Address
79 New Oxford Street
City
London
Postcode
WC1A 1DG
Country
United Kingdom

Scientific contact point

Organisation
Glaxosmithkline Research & Development Limited
Contact name
EU GSK Clinical Trials Call Center

Public contact point

Organisation
Glaxosmithkline Research & Development Limited
Contact name
EU GSK Clinical Trials Call Center

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ongoing, recruiting 30 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ongoing, recruiting
Pharmaceutical Research Associates Group B.V.
Program Management, Van Swietenlaan 6, 9728 NZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2026-05-12 2026-05-18

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2026-03-13 Netherlands Acceptable
2026-05-06
2026-05-06